Integrated Biopharma

Integrated Biopharma EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Integrated Biopharma (INBP) as of Oct 26, 2026 is 4.61. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 37.08 — a change of -87.57% (lower).

EV/EBIT

4.61

YoY

-87.57%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Integrated Biopharma is 2025 4.61 . EV/EBIT (Enterprise Value to EBIT) of Integrated Biopharma was 2024 37.08 . It decreases by -87.57% lower compared to the previous year.

The Integrated Biopharma EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
5.49 USD
Jan 1, 2019
3.44 USD
Jan 1, 2020
2.86 USD
Jan 1, 2021
1.61 USD
Jan 1, 2022
3.39 USD
Jan 1, 2023
77.56 USD
Jan 1, 2024
37.08 USD
Jan 1, 2025
4.61 USD
The Integrated Biopharma EV/EBIT history
YEAREV/EBITYoY
4.61-87.57%
37.08-52.19%
77.56+2,187.50%
3.39+110.71%
1.61-43.65%
2.86-17.03%
3.44-37.35%
5.49+88.13%
2.92-33.67%
4.40-55.87%
9.98+44.91%
6.88+3,342.23%
0.20+900.00%
0.02—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Integrated Biopharma Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Integrated Biopharma's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Integrated Biopharma's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Integrated Biopharma's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Integrated Biopharma grows earnings faster than its peers.

Integrated Biopharma Stock analysis

What does Integrated Biopharma do? Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry. Integrated Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integrated Biopharma stock

EV/EBIT (Enterprise Value to EBIT) of Integrated Biopharma is 4.61 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Integrated Biopharma changed from 37.08 to 4.61, representing a -87.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Integrated Biopharma since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Integrated Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Integrated Biopharma

All Key Metrics — Integrated Biopharma